Pelthos Therapeutics Inc.
Biopharma with an approved gel for molluscum, advancing a nitric oxide-based pipeline.
PTHS | NYSE
Overview
Corporate Details
- ISIN(s):
- US1711261057
- LEI:
- Country:
- United States of America
- Address:
- 4020 STIRRUP CREEK DRIVE, 27703 DURHAM
- Website:
- https://ir.pelthos.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Pelthos Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for patients with unmet medical needs. The company's lead product, ZELSUVMI™ (berdazimer topical gel, 10.3%), is approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum. In addition to ZELSUVMI™, Pelthos Therapeutics is advancing a pipeline of product candidates based on its proprietary nitric oxide-based technology platform, NITRICIL™. The company was launched by Ligand Pharmaceuticals in April 2024 and completed a merger with Channel Therapeutics in July 2025 to support its commercialization efforts.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Pelthos Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pelthos Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pelthos Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
